Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bordignon

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Science (New York, N.Y.)|March 15, 1991
An in vivo model of somatic cell gene therapy for human severe combined immunodeficiencyG Ferrari, S Rossini, R Giavazzi, et al.
Cancer Research|July 29, 1998
The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytesK Fleischhauer, L Gattinoni, P Dalerba, et al.
The Journal of Experimental Medicine|September 22, 1998
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineageR Lupetti, P Pisarra, A Verrecchia, et al.
Annals of the New York Academy of Sciences|January 1, 1987
Retroviral vector-mediated gene transfer and expression in nonhuman primates following autologous bone marrow transplantationA Gillio, C Bordignon, N Kernan, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1989
Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cellsC Bordignon, S F Yu, C A Smith, et al.
Blood|June 1, 1990
Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemiaM Hauch, M V Gazzola, T Small, et al.
Science (New York, N.Y.)|June 13, 1997
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemiaC Bonini, G Ferrari, S Verzeletti, et al.
Blood|November 1, 1989
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplantsN A Kernan, C Bordignon, G Heller, et al.
Annals of the New York Academy of Sciences|January 1, 1987
The role of residual host immunity in graft failures following T-cell-depleted marrow transplants for leukemiaC Bordignon, N A Kernan, C A Keever, et al.
Human Gene Therapy|August 1, 1993
Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCIDC Bordignon, F Mavilio, G Ferrari, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Science (New York, N.Y.)|March 15, 1991
An in vivo model of somatic cell gene therapy for human severe combined immunodeficiencyG Ferrari, S Rossini, R Giavazzi, et al.
Cancer Research|July 29, 1998
The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytesK Fleischhauer, L Gattinoni, P Dalerba, et al.
The Journal of Experimental Medicine|September 22, 1998
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineageR Lupetti, P Pisarra, A Verrecchia, et al.
Annals of the New York Academy of Sciences|January 1, 1987
Retroviral vector-mediated gene transfer and expression in nonhuman primates following autologous bone marrow transplantationA Gillio, C Bordignon, N Kernan, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1989
Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cellsC Bordignon, S F Yu, C A Smith, et al.
Blood|June 1, 1990
Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemiaM Hauch, M V Gazzola, T Small, et al.
Science (New York, N.Y.)|June 13, 1997
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemiaC Bonini, G Ferrari, S Verzeletti, et al.
Blood|November 1, 1989
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplantsN A Kernan, C Bordignon, G Heller, et al.
Annals of the New York Academy of Sciences|January 1, 1987
The role of residual host immunity in graft failures following T-cell-depleted marrow transplants for leukemiaC Bordignon, N A Kernan, C A Keever, et al.
Human Gene Therapy|August 1, 1993
Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCIDC Bordignon, F Mavilio, G Ferrari, et al.
Pageof 10